PAHC
Phibro Animal Health Corporation
Drug Manufacturers - Specialty & Generic · Healthcare · United States
38.86
close · 2026-10-29
value
67
cheaper than peers67
quality
53
stronger fundamentals53
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.07× | 91 |
| EV to EBITDA | 9.29× | 65 |
| forward P/E | 10.10× | 61 |
| price to book | 4.09× | 36 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 29.7% | 90 |
| operating margin | 10.6% | 59 |
| revenue growth | 4.8% | 42 |
| debt to equity | 206.4% | 24 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$19.3M |
| employees | 2,605 |
| first trade | 2014-04-11 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-09-02 |
Annual history
| measure | 2026 | 2025 | 2024 | 2023 |
| diluted eps | 2.43 | 1.19 | 0.06 | 0.81 |
| free cash flow | $9.9M | $41.8M | $46.4M | -$38.5M |
| net income | $99.7M | $48.3M | $2.4M | $32.6M |
| revenue | $1.52B | $1.30B | $1.02B | $977.9M |
| unusual items | -$12.6M | -$7.9M | -$23.9M | -$2.5M |